StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.40−0.01 (-2.37%)

Close on Nov 20, 2026Market cap $728.18KP/E –Yield –

Aptevo Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Aptevo Therapeutics's free cash flow for the twelve months ending Dec 31, 2022 was -$21.05M. For fiscal 2022 it was -$21.05M. The highest annual figure on record is -$21.05M in fiscal 2022.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$21.05M–
FY2021Dec 31, 2021-$22.39M–
FY2020Dec 31, 2020-$29.41M–
FY2019Dec 31, 2019-$42.54M–
FY2018Dec 31, 2018-$52.40M–
FY2017Dec 31, 2017-$42.98M–
FY2016Dec 31, 2016-$39.37M–
FY2015Dec 31, 2015-$50.29M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$5.94M–
Q3 FY2022Sep 30, 2022-$6.90M–
Q4 FY2021Dec 31, 2021-$4.00M–
Q3 FY2021Sep 30, 2021-$5.26M–
Q2 FY2021Jun 30, 2021-$5.44M–
Q1 FY2021Mar 31, 2021-$7.70M–
Q4 FY2019Dec 31, 2019-$5.10M–
Q3 FY2019Sep 30, 2019-$7.55M–
Q2 FY2019Jun 30, 2019-$15.89M–
Q1 FY2019Mar 31, 2019-$14.00M–
Q4 FY2018Dec 31, 2018-$7.34M–
Q3 FY2018Sep 30, 2018-$11.51M–
Q2 FY2018Jun 30, 2018-$16.10M–
Q1 FY2018Mar 31, 2018-$17.45M–
Q4 FY2017Dec 31, 2017-$15.72M–
Q3 FY2017Sep 30, 2017-$1.75M–
Q2 FY2017Jun 30, 2017-$12.69M–
Q1 FY2017Mar 31, 2017-$12.82M–
Q4 FY2016Dec 31, 2016-$7.24M–
Q3 FY2016Sep 30, 2016-$88.00K–

More Aptevo Therapeutics figures

See a number that looks wrong?